Darzalex

Pharmaceutical product

Business Health US & Canada

J&J beats Q1 estimates

Johnson & Johnson topped quarterly expectations and boosted its outlook due to strong cancer drug sales.

J&J’s first-quarter profit beats estimates even as Stelara sales disappoint CTV News — Apr 14, 11:55 AM
J&J’s first-quarter profit beats estimates even as Stelara sales disappoint The Globe and Mail — Apr 14, 11:28 AM
J&J’s First-Quarter Sales Grow on Cancer-Drug Strength Wall Street Journal — Apr 14, 10:20 AM
Johnson & Johnson Non-GAAP EPS of $2.70 beats by $0.02, revenue of $24.06B beats by $450M Seeking Alpha — Apr 14, 10:21 AM
J&J's first-quarter profit beats estimates even as Stelara sales disappoint - Reuters Reuters — Apr 14, 11:50 AM
Earnings Snapshot: Johnson & Johnson tops Q1 expectations; boosts full-year outlook and increases quarterly dividend Seeking Alpha — Apr 14, 10:52 AM
J&J raises 2026 outlook as oncology products power Q1 beat Seeking Alpha — Apr 14, 10:50 AM
Johnson & Johnson raises dividend by 3.1% to $1.34 Seeking Alpha — Apr 14, 10:25 AM
Johnson & Johnson in charts: Q1 Innovative Medicine rises 11.2% as DARZALEX leads growth Seeking Alpha — Apr 14, 10:51 AM